MedPath

Key Specialized Monitoring of Clinical Safety of Pudilan Xiaoyan Oral Liquid in the Real World

Conditions
Respiratory Infectious Diseases
Registration Number
NCT04031651
Lead Sponsor
China Academy of Chinese Medical Sciences
Brief Summary

To obtain the characteristics of adverse reactions/incidents, analyze the influencing factors and calculate the incidence of adverse reactions/incidents monitored by Pudilan Xiaoyan Oral Liquid in key specialties in the real world, so as to provide a basis for clinical safe and rational drug use.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
10000
Inclusion Criteria
  • (1)Upper respiratory tract infection patients using Pudilan antiphlogistic oral liquid ;
  • (2)Aged between 18 and 80.
Read More
Exclusion Criteria
  • Lactating women, pregnant women, pregnant planners, psychiatric patients, etc.
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Incidence of Adverse Drug Reaction7 days

Incidence of Reduning Injection'Adverse Drug Reaction(ADRs)and Identify Factors That Contributed to the Occurrence of the Adverse Drug Reaction

Secondary Outcome Measures
NameTimeMethod
The Ratio of Body Temperature to Normal7 days

The Ratio of Body Temperature to Normal(Lower Than 37.3ºC)

Change of liver function7 days

Observation of liver function in at least 3000 patients before and after medication.The liver function includes glutamic-pyruvic transaminase,glutamic-oxalacetic transaminase.To observe whether the above liver function indexes appear abnormal once after medication.

Change of renal function7 days

Observation of renal function in at least 3000 patients before and after medication.The renal function includes creatinine,usea nitrogen.To observe whether the above renal function indexes appear abnormal once after medication.

© Copyright 2025. All Rights Reserved by MedPath